Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
SEC Accession No. 0001144204-19-015715
Filing Date
2019-03-25
Accepted
2019-03-25 08:46:26
Documents
12
Period of Report
2019-05-08

Document Format Files

Seq Description Document Type Size
1 PRELIMINARY PROXY STATEMENT tv511325-prem14a.htm PREM14A 3489226
2 GRAPHIC lg_ampliphi.jpg GRAPHIC 181243
3 GRAPHIC lg_ladenburg.jpg GRAPHIC 44938
4 GRAPHIC sg_ladenburg-thalmann.jpg GRAPHIC 26604
5 GRAPHIC tv511325_chart-table.jpg GRAPHIC 171822
6 GRAPHIC tv511325_img1.jpg GRAPHIC 125674
7 GRAPHIC tv511325_img2.jpg GRAPHIC 91061
8 GRAPHIC tv511325_img3.jpg GRAPHIC 200251
9 GRAPHIC tv511325_proxy1.jpg GRAPHIC 885889
10 GRAPHIC tv511325_proxy2.jpg GRAPHIC 468415
11 GRAPHIC tv511325_proxy3.jpg GRAPHIC 477822
12 GRAPHIC tv511325_proxy4.jpg GRAPHIC 429725
  Complete submission text file 0001144204-19-015715.txt   7753782
Mailing Address 3579 VALLEY CENTRE DRIVE SAN DIEGO CA 92130
Business Address 3579 VALLEY CENTRE DRIVE SAN DIEGO CA 92130 804-827-2524
AmpliPhi Biosciences Corp (Filer) CIK: 0000921114 (see all company filings)

EIN.: 911549568 | State of Incorp.: WA | Fiscal Year End: 1231
Type: PREM14A | Act: 34 | File No.: 001-37544 | Film No.: 19701403
SIC: 2836 Biological Products, (No Diagnostic Substances)